Sr. Director - Clinical Operations Program Leader (COPL) - Neurology

BlueRock Therapeutics

Cambridge, Massachusetts Onsite Clinical Development Full-time

About this role

Who is BlueRock?

BlueRock Therapeutics LP is a clinical stage cell therapy harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRT-DA01) for the treatment of Parkinson’s disease and OpCT-001 for the treatment of primary photoreceptor diseases are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves.

What Are We Doing?

Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.

We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.

We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cutting-edge cellular therapies to impact patients’ lives.

Our Pipeline Vision:

Neurology:

BlueRock is advancing an innovative pipeline of cell therapies in neurology, focused on addressing the urgent needs of patients with neurodegenerative and neurological disorders. Our lead neurology program, bemdaneprocel (DA01), is a first-in-class, allogeneic cell therapy designed to replace lost dopaminergic neurons in patients with Parkinson’s disease. This program is currently in phase 3 development with the exPDite-2 clinical trial ongoing in the US, Canada, and Australia. Additional neurology pipeline assets, including DA02 and MG0X, are in research phase targeting other high-impact neurological conditions.Our goal is to restore function, slow or halt disease progression, and transform the standard of care for patients with debilitating neurological diseases.

Ophthalmology:

BlueRock is expanding its innovative cell therapy portfolio into ophthalmology, with a focus on addressing unmet medical needs in retinal diseases. Our lead ophthalmology program, OpCT001, is a first-in-class, allogeneic cell therapy candidate designed to replace lost or damaged retinal pigment epithelial (RPE) cells in patients with advanced retinal disorders, such as geographic atrophy secondary to age-related macular degeneration (AMD). OpCT001 leverages our CELL+GENE™ platform to generate authentic, functional RPE cells from pluripotent stem cells, with the goal of restoring vision and halting disease progression.

BlueRock is committed to scientific excellence, operational rigor, and the highest standards of ethics and compliance. The company fosters an inclusive, collaborative environment where innovation, diversity, and patient-centricity drive every decision.

About the Role:

The Clinical Operations Program Leader (COPL) is responsible for the strategic planning, execution, and oversight of BlueRock’s clinical development programs across multiple studies and geographies specifically for our Neurology programs. This leadership role ensures alignment with corporate goals, regulatory requirements, and timelines, while fostering cross-functional collaboration and operational excellence in the advancement of next-generation cell therapies.